Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

BTIG analyst Mark Massaro maintains a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and adjusts the price target to $7 following a 1-40 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 5:17 pm

Ginkgo Bioworks shares are trading higher after the company reported better-than-expected Q2 revenue results.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 12:32 pm

Ginkgo Bioworks Holdings has projected its FY24 revenue to be between $170 million and $190 million, compared to the estimated $179.502 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:05 pm

Ginkgo Bioworks Holdings (NYSE:DNA) reported Q2 2024 GAAP EPS of $(0.11), missing the $(0.07) estimate, but achieved sales of $56.21M, beating the $43.14M estimate. Sales decreased by 30.24% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:04 pm

Syngenta has partnered with Ginkgo Bioworks to enhance the launch of biological products. This collaboration aims to leverage Ginkgo's expertise in synthetic biology to develop sustainable agricultural solutions.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:03 am

Cathie Wood's Ark Invest sold $3.25M worth of Tesla shares despite a recent rally driven by strong Q2 deliveries. Ark Invest also made trades involving Teladoc Health, Intellia Therapeutics, Verve Therapeutics, Archer Aviation, Ginkgo Bioworks, AeroVironment, and Blade Air Mobility.

Portfolio Pulse from Benzinga Neuro

July 05, 2024 | 2:59 pm

Cathie Wood's Ark Invest made significant trades in Roku Inc and Coinbase Global Inc amidst a volatile market. Ark's ETFs acquired $7.3M worth of Roku shares and sold $703K worth of Coinbase shares. Other trades included selling Ginkgo Bioworks and Teladoc Health shares, and buying 10X Genomics and Intellia Therapeutics shares.

Portfolio Pulse from Benzinga Neuro

June 27, 2024 | 3:33 am

BTIG analyst Mark Massaro maintains a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and lowers the price target from $0.5 to $0.2.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:44 pm

Cathie Wood-led Ark Invest made significant trades on June 25, 2024, involving NVIDIA Corp (NVDA) and Roku Inc (ROKU). ARKQ sold $4.3M worth of NVIDIA shares, while ARKK and ARKW bought $5.3M worth of Roku shares. Other trades included sales of Ginkgo Bioworks (DNA) and Zoom (ZM), and purchases of Arcturus Therapeutics (ARCT), 10X Genomics (TXG), PagerDuty (PD), Blade Air Mobility (BLDE), and Markforged (MKFG).

Portfolio Pulse from Benzinga Neuro

June 26, 2024 | 2:27 am

Ginkgo Bioworks has begun implementing a previously announced restructuring plan, which includes a 35% workforce reduction and aims to cut labor expenses by 25%. The initial phase will incur at least $12 million in severance costs. Further details will be provided in the company's Q2 2024 earnings call and subsequent reports.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 9:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.